The Road to an Improved Magic Bullet: Combating Antibiotic Resistance in the Genetic Era by Abraham, Jibin J.
Regis University 
ePublications at Regis University 
All Regis University Theses 
Spring 2018 
The Road to an Improved Magic Bullet: Combating Antibiotic 
Resistance in the Genetic Era 
Jibin J. Abraham 
Regis University 
Follow this and additional works at: https://epublications.regis.edu/theses 
Recommended Citation 
Abraham, Jibin J., "The Road to an Improved Magic Bullet: Combating Antibiotic Resistance in the Genetic 
Era" (2018). All Regis University Theses. 878. 
https://epublications.regis.edu/theses/878 
This Thesis - Open Access is brought to you for free and open access by ePublications at Regis University. It has 
been accepted for inclusion in All Regis University Theses by an authorized administrator of ePublications at Regis 
University. For more information, please contact epublications@regis.edu. 
  
 
 
 
 
 
 
 
THE ROAD TO AN IMPROVED MAGIC BULLET: 
COMBATING ANTIBIOTIC RESISTANCE IN THE GENETIC ERA 
 
 
 
A thesis submitted to 
Regis College 
The Honors Program 
in partial fulfillment of the requirements 
for Graduation with Honors 
by 
Jibin J. Abraham 
 
 
 
May 2018 
 
 
 
 
 
ii 
 
Thesis written by 
Jibin J. Abraham 
 
 
 
 
 
Approved by 
 
 
 
 
______________________________________________________________________ 
Thesis Advisor 
 
 
 
______________________________________________________________________ 
Thesis Reader 
 
 
 
 
Accepted by 
 
 
 
______________________________________________________________________ 
Director, University Honors Program 
     
  
  
 iv 
 
TABLE OF CONTENTS 
 
Preface and Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii 
List of Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi 
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
Chapter 1: Introduction to Microbiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 
  1a. Brief history of Microbiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 
  1b. Koch’s postulates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 
Chapter 2: Antibiotic Resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 
  2a. History of antibiotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 
  2a. i. Paul Ehrlich and the magic bullet . . . . . . . . . . . . . . . . . . . . . . . . . . 10 
  2a. ii. Alexander Fleming, Howard Florey, Ernest Chain, and the discovery 
of penicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 
  2b. Introduction to antibiotics and modes of action . . . . . . . . . . . . . . . . . . . . . . 18 
  2b. i. Cell wall synthesis inhibition | β-lactam antibiotics . . . . . . . . . . . . 20 
  2b. ii. DNA synthesis inhibition | Fluoroquinolone antibiotics . . . . . . . . 22 
  2b. iii. Protein synthesis inhibition | Tetracycline antibiotics . . . . . . . . . 24 
 v 
 
TABLE OF CONTENTS 
2c. Threats of antibiotic resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 
  2c. i. How antibiotic resistance works . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 
  2c. ii. How human use of antibiotics contributes to resistance . . . . . . . . 33 
   2c. iii. How can we address antibiotic resistance . . . . . . . . . . . . . . . . . . 38 
  2c. iv. Antibiotic resistance diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 
Chapter 3: CRISPR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 
  3a. Introduction to CRISPR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 
  3b. Clinical application of CRISPR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 
  3b. i. CRISPR and detecting antibiotic resistance . . . . . . . . . . . . . . . . . . 51 
  3b. ii. CRISPR and potential antibiotic therapy . . . . . . . . . . . . . . . . . . . 54 
   3c. A CRISPR cautionary case . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56 
Chapter 4. How the global community ought to proceed in using CRISPR to combat 
antibiotic resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59 
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63 
Image References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 
 
 
 vi 
 
LIST OF FIGURES 
 
Figure 1. Cork bark cells by Robert Hooke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 
Figure 2. Penicillium mold by Alexander Fleming . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 
Figure 3. Structure of penicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 
Figure 4. MEGA Plate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 
Figure 5. Kirby-Bauer assay of MRSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 
  
 vii 
 
Acknowledgements 
 I would first like to thank my thesis advisor Dr. Gena Nichols, professor of 
Biology, for her assistance throughout the thesis writing process. Her expertise, patience, 
and reassurance were greatly welcomed during the months of research, writing, and 
revision. I would next like to thank my thesis reader Dr. Stephen Ray, professor of 
Physics, for his commentary on the thesis which was instrumental in the style of writing 
and in limiting the scope of the paper. I would like to thank Dr. Cath Kleier, professor of 
Biology, who is the interim Director of the Honors Program and my Biology program 
advisor for her guidance throughout my 4 years at Regis University, and for the many 
opportunities she has provided me in my undergraduate career. I would like to thank Dr. 
Lara Narcisi, professor of English, who is the Associate Director of the Honors Program, 
and was first to welcome me to the Honors Program first-year seminar. There are 
countless other faculty and staff I would like to thank who have in some way left lasting 
impressions on my time at Regis and, perhaps more importantly, on my character in 
moving forward. Lastly, I must thank my family, and my friends in the Honors Program, 
without whose support this would not have been possible.
 1 
 
Introduction 
 Humans have used antibiotics far longer than most may realize. The oldest known 
evidence for the presence of antibiotics in humans has been dated back to approximately 
C.E. 350 – 500 where tetracycline was found in human bones (Nelson et al., 2010). 
Through the millennia, earlier civilizations applied herbaceous poultices, ate strange 
soups, or pressed soils and molds into wounds to treat bacterial infections. At the time the 
people believed these remedies forced out evil spirits and or appeased gods of disease, 
and were not aware that such illnesses were bacterial in nature. These early treatments 
were sometimes successful because the antibiotics naturally produced by bacteria found 
in plants, clay, and soil were likely enough to kill the infectious bacteria which would 
cure the wound or disease, acting as a rudimentary chemotherapy. 
 Since the discovery of antibiotics in the 1930s and the clinical application of 
antibiotics in the 1940s, mortality rates from bacterial infections have been significantly 
reduced where there is access to antibiotics. However, the widespread use of antibiotics 
has put substantial evolutionary pressure on bacteria which results in a rapid selection for 
microorganisms resistant to these treatments. In less than 100 years after the discovery 
and clinical application of the first antibiotic, antibiotic resistance threatens to outpace the 
current management of infections. This makes antibiotic resistance one of the most 
significant global human health threats, with bacteria developing resistance to the current 
available classes of antibiotics faster than new ones are discovered or synthesized. 
Medical procedures including diabetes management, organ transplants, and cesarean 
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sections (C-sections) become significantly riskier if post-operative care is not effective in 
minimizing infections wherever possible. 
A critical factor contributing to the unnecessary use of antibiotics is the lack of 
rapid and accurate diagnostic tests that can identify the nature of an infectious agent and 
anticipate pathogenic sensitivities to various drug classes. Successfully addressing this 
issue will facilitate a shift in antibiotic discovery and synthesis towards more narrow-
spectrum, pathogen-specific antibiotics to slow the evolution of resistant bacteria, as well 
as promote antimicrobial stewardship. Current methods for addressing antibiotic 
resistance are too slow and ineffective. Recent efforts have called attention to the need 
for a new approach to detection and treatment, and there exists a potential technology that 
is fast, specific, controllable, and cheap. This will impact our current approaches to 
antimicrobial stewardship, which the Society for Healthcare Epidemiology of America 
(SHEA) defines as “coordinated strategies to improve the use of antimicrobial 
medications with the goal of enhancing patient health outcomes, reducing resistance to 
antibiotics and decreasing unnecessary cost” (Society for Healthcare Epidemiology of 
America, 2017). 
At the precipice of a new era in healthcare in the developed world, one where 
most decisions may soon be personalized to a patient’s genetics and background, the 
potential for disruption in the medical field is significant. The development of CRISPR 
technology has much excitement and hype around its possible utilization, and rightly so, 
as it may hold the key to placing a new era of robust, long-lasting treatments in our reach, 
including applications to resolve previously untreatable conditions and fatal infections. 
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There are many articles that report on this as though this may be the end-all-be-all of 
medical treatment in the future. However, the rate at which this is developing may be too 
quick for key discussions regarding its future use, and as such may lead to hasty 
conclusions and decisions, delaying and possibly hindering its implementation and 
making the process much more challenging than it needs to be. Considering the current 
application of the technology was first identified one decade ago in 2008, there is still 
much to research before integrating it as a replacement for other working methods. It may 
just be fitting, however, that a rapidly-developing field may be able to address a global 
issue rapidly outpacing our ability to fight it: antibiotic resistance. First, by using 
CRISPR technology in detection and diagnosis outside the body, then possibly to 
supplement or enhance treatment within the body, and, perhaps in another decade or so, 
as a replacement for antibiotics altogether. 
To explore this topic, the thesis will begin with an introduction to microbiology to 
place this conversation within the context of physical scale. To establish the urgency of 
antibiotic resistance, the second chapter is dedicated to describing the problem, its 
history, current approaches, and why more needs to be done. The second chapter will also 
introduce Paul Erhlich who coined the term “magic bullet” as an idealistic gold standard 
and whose work had profound effects on the state of healthcare and medical science in 
the decades since his time. CRISPR, the new technology that places us in a new era in 
medicine, is covered in the third chapter. Finally, the fourth chapter will briefly propose 
general suggestions surrounding the approach to the problem of antibiotic resistance as to 
be addressed by CRISPR. 
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1. Introduction to Microbiology 
1a. Brief history of microbiology. 
  The discovery of bacteria is credited to Anton van Leeuwenhoek (1632 – 1723), 
who is considered the father of the field of microbiology. By trade, van Leeuwenhoek 
was a Dutch textile merchant who did not receive a formal education. His work required 
him to inspect weaves and fibers of textile products from different manufacturers, and 
microscopes provided the best way to inspect the materials. Anton van Leeuwenhoek 
became very much intrigued by the manufacture of glass and its various intrinsic 
properties. In 1671, he developed a microscope powerful enough to view bacteria using 
only sunlight to backlight the subject. He observed what he called ‘animalcules,’ which 
are now known as bacteria. Van Leeuwenhoek was the first to observe bacteria, and by 
his death in 1723 he had invented more than 400 microscopes. His contributions 
developed and established the field of microbiology, which is the study of 
microorganisms. 
 While various scientific societies and researchers began to describe bacteria and 
its various forms, many were unsure of how bacteria formed. In September of 1655, an 
English natural historian named Robert Hooke (1635 – 1703) published Micrographia, 
which was the first book describing microscopic observations. One of Hooke’s most 
famous observations was of two pieces of thinly-sliced cork, in which he was able to see 
rigid box-like structures comprising the entire cork. These structures Hooke had observed 
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are now known to be the cell walls of the cork bark, and Hooke called these structures 
‘cells’ because they resembled the sleeping quarters of monks, which the monasteries 
often referred to as cells. 
 
 
  
1b. Koch’s postulates. 
While in ancient civilizations the causes of infections were unknown, it is now 
known that the majority of infections are bacterial or viral in nature. The invention of van 
Leeuwenhoek’s microscope allowed for research on microorganisms which had not been 
observed before 1671. As soon as microscopes were more widely distributed, it was 
Figure 1. Robert Hooke’s sketches of two thinly-sliced pieces of cork bark at 50x 
magnification in which he viewed empty space enclosed by box-like frames, and 
termed these ‘cells’ (Hooke, 1665). 
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theorized that bacteria could be responsible for various infections, and it seemed clear 
that specific species or forms were causative agents for different infectious diseases 
(pathogens). Indirect evidence of microorganism pathogenicity was provided by the 
widespread adoption and implementation of sterile technique in surgery and the washing 
of hands in hospital settings which reduced the number of infections and post-operational 
recovery time. However, there was not enough evidence to definitively prove that 
bacteria caused disease. 
Robert Koch (1843 – 1910) was a German physician. He is called the father of 
medical microbiology for having developed and defined the concept of infectious disease 
and for providing convincing evidence. Koch’s early work studied anthrax which is a 
disease that generally affects cows, but can also affect humans. He was able to isolate a 
bacterium known as Bacillus anthracis from the blood of cows showing symptoms of 
anthrax, which demonstrated that bacteria were present in the blood of infected 
individuals. However, this was only the association of B. anthracis with the symptoms of 
disease and not proof that the bacterium is the causative agent, or pathogen. In 1877, he 
developed a framework in which one could confirm whether a bacterium was the 
pathogen in an infection. The four postulates are as follows: 
1. Isolate the pathogen from infected individuals. The suspected pathogen must 
be present in all infected individuals and absent from healthy individuals. 
2. The suspected pathogen must be developed in a pure laboratory culture. 
3. Cells from the pure laboratory culture must then be injected into a healthy, 
uninfected test subject(s) (usually a mouse) which must then develop an 
infection and present the symptoms or die. 
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4. The suspected pathogen must be reisolated from the organism(s) infected in 
postulate 3 and shown to be the same pathogen as the original isolated from 
postulate 1. 
When studying anthrax, Koch had shown that bacteria was present in the blood of 
infected organisms (postulate 1). He realized that the bacterium could be grown outside 
of a host in a fluid containing all necessary nutrients and retain the ability to cause 
disease when injected into a healthy organism (postulates 2 & 3). Koch injected a small 
volume of blood containing the bacterium into a healthy, uninfected mouse which 
developed anthrax soon after (postulate 3). He drew some blood from the newly-infected 
mouse and injected that blood into a second healthy, uninfected mouse which then also 
showed the characteristic symptoms (postulate 3). However, Koch knew that bacteria can 
exhibit different forms (morphologies) and look different in a lab culture, and may 
express properties that can present as different symptoms in an infection. Koch added the 
4th postulate to minimize any possibility of confusion or misattributing disease to the 
wrong pathogen. With Koch’s postulates, it was finally possible to demonstrate that 
bacteria caused diseases, and various infectious agents were soon identified and 
associated with their respective infections. 
Why does this matter? These postulates form the basis of identifying pathogens 
and diagnosing infectious diseases. Of course, the exact method employed by Koch 
would not be ideal in diagnosing general infections today as it would require significant 
resources, a large number of rats, and time that may not be available to an infected 
individual. However, this is still a method by which infectious agents are identified. In 
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the time since Koch, there are new ways to identify pathogens, which will be covered 
later in this thesis. 
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2. Antibiotic Resistance 
2a. History of antibiotics. 
 Prior to the discovery of bacteria, the identification of bacteria as infectious 
agents, and the discovery of antibiotics, people desperately sought treatments and cures 
for their illnesses, believing and theorizing various causes of disease. As a result, bizarre 
treatments have been recorded throughout history, such as using leeches to remove ‘bad’ 
blood, following elaborate rituals to appease gods and spirits, applying various pastes and 
powders to wounds, drinking questionable tonics, and even smoking or injecting crystal 
methamphetamine, among other suspicious prescriptions. 
Several ancient treatments have demonstrated some efficacy against infectious 
disease, and have been discussed for clinical application in recent years. However, this is 
because the successful treatments delivered some form of antibiotic, though it was not 
known at the time. For example, the Egyptians applied a poultice of moldy bread to 
infected wounds, in which the mold produced antibiotics and killed the infectious 
bacteria, effectively reducing the period of illness and possibly preventing death. In 1971, 
Chinese researchers at the Institute of Traditional Medicine in Beijing looked at a 4th 
century CE text and discovered a method to extract artemisinin from Artemisia plants 
(used in Chinese medicine for millennia) that proved to be an effective treatment against 
drug-resistant malaria and is now used around the world (Hsu, 2006). Another recent 
study found a nearly 1,000-year-old recipe for an eye salve of garlic and onion that was 
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comparably effective to the current treatment of choice for killing a modern superbug 
(Harrison et al., 2015). The same manuscript, however, also contained salves against 
elves, and recommended whipping lunatics with a whip made of porpoise skin as a cure. 
Evidently the manuscript writer did not truly know what was effective or how the 
supposed cures worked, but the mechanisms for treatment can be understood and 
identified today. However, to understand how these can studied, it is perhaps pertinent to 
understand some of the context and work that made such an advancement possible. 
 
2a. i. Paul Ehrlich and the magic bullet. 
 Some individuals actively sought better treatment options, looking for ways to 
treat the population at large and minimize infection. Through Koch’s work, bacteria were 
shown to be a source of infection, and researchers set their sights on developing 
diagnostics and treatments for bacterial infections. German Jewish physician Paul Ehrlich 
(1854 – 1915) was one such individual, notable for his contributions to early diagnostic 
and pharmaceutical science, oncology, for fathering the concept of chemotherapy, among 
other things. Perhaps his most prestigious accolade is his Nobel Prize in Physiology or 
Medicine which he received in 1908 for his molecular side-chain theory of immunity. 
Ehrlich’s career is worth briefly examining because he was poised to set the stage for 
drug development in a period that would see the rise of the chemical industry, and recent 
advances have set a similar stage for the rise of the genetic industry, of which one recent 
advancement will be discussed later in this paper. 
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At the start of his research career in the 1870s, Paul Ehrlich developed a personal 
interest in the use of dyes that could stain tissue. His older cousin Carl Weigert (1845 – 
1904) developed the use of dyes like aniline to stain anatomical tissue and preferential 
staining of bacteria, so Erlich’s interest was certainly an inspired one (Jay, 2001). 
Pursuing this, he developed and published a doctoral thesis about his methods for staining 
different types of cells—a process during which he discovered mast cells which are 
important components of the normal immune system (Crivellato, Beltrami, Mallardi, & 
Ribatti, 2003). He became a physician at the Charité in Berlin, Europe’s largest university 
hospital, where the head of the clinic was Friedrich Theodor von Frerichs (1819 – 1885), 
who was a professor of internal medicine well-recognized for his contributions 
surrounding liver and kidney diseases. Von Frerichs was interested in incorporating 
laboratory diagnostics into clinical treatment and was very accommodating of Ehrlich’s 
staining experiments in animals (Travis, 1989). Through several years of staining tissue 
samples from patients, Ehrlich became familiar with various dyes intended to show 
different structures, and was even able to differentiate between bacterial infections based 
on stains which allowed him to provide diagnostic advice for treatment. 
Ehrlich was greatly inspired by Koch’s research and the new concepts 
surrounding infection. When he worked with Koch in the early 1880s, he used his 
acquired knowledge of dyes to improve several of the staining techniques Koch used and 
demonstrated his advanced ability to differentiate bacteria in this manner (Thorburn, 
1983). Realizing the potential for further application, Ehrlich expressed interest in 
developing therapeutic uses for the dyes. Koch offered Ehrlich lab space and assistants in 
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1890, and Ehrlich pushed his animal experimentation. Ehrlich observed something that 
year: one of the dyes, methylene blue, not only stained the tuberculosis bacteria in the 
mice he was feeding the dye to, but it also deposited in the axons of the nerve cells of 
mice without dyeing anything else (Winau, Westphal, & Winau, 1996). The realization 
came that some dyes exclusively stained bacteria while others also affected a test 
subject’s own cells. This inspired Ehrlich to reason that there may be chemical 
compounds he could use to selectively stain bacteria within an individual, and perhaps 
could selectively kill infectious agents without harming the human body. He would 
eventually come to call this idea the “magic bullet.” 
The magic bullet concept was the idea of injecting a chemical agent into the blood 
to specifically target and kill infectious pathogens without harming any human cells. For 
15 years he continued to work with mice and tested various dyes, poisons, and toxins to 
find a way to accomplish a therapy for treating infections. In 1896, Ehrlich founded his 
own institute, The Institute for Serum Research and Serum Testing, in Steglitz, Germany, 
and it moved to Frankfurt, Germany three years later where it was renamed The Royal 
Prussian Institute for Experimental Therapy (Bäumler, 60-61). He turned his focus to 
trypanosomes in 1901 after reading papers wherein it was revealed these microorganisms 
caused sleeping sickness. Trypanosomes are a parasitic protozoan, which are not bacteria, 
but are large microorganisms which made them ideal for evaluating stain effectiveness 
because they are easier to see. Ehrlich and his assistant, Dr. Kiyoshi Shiga (1871 – 1957) 
after whom the bacterial genus Shigella is named, tested several hundred arsenic-based 
compounds. Initially, results were less than encouraging because the dyes would stain 
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both the bacterial cells and the cells of the mice they were testing on. In 1903, after 
testing more than 500 compounds, Ehrlich found a substance that killed trypanosomes 
and effectively cured the mice of sleeping sickness (Ehrlich & Shiga, 1904; Felsenfeld, 
1957). He called this trypan red. This victory was short-lived, however, as it became 
rapidly evident that the compound could not kill all trypanosomes, and soon the 
trypanosomes developed a sort of tolerance to the trypan red, in which case the effective 
dosage was no longer enough to kill the trypanosomes. However, this was enough to 
excite Ehrlich and he began to pursue this further in the hopes of finding a real magic 
bullet. 
In 1904, Ehrlich turned his focus to syphilis which is caused by the bacterium 
Treponema pallidum. Syphilis is sexually-transmitted disease in which the first and 
second stages present as sores and rashes, and can ultimately result in neuronal diseases 
and infection of the brain. Ehrlich was unsatisfied with the standard treatment of syphilis 
at the time which utilized inorganic mercury compounds that were mildly effective at 
best, but was also delivered in toxic concentrations and caused undesirable side effects 
(Tampa, Sarbu, Matei, Benea, & Georgescu, 2014). In 1907, several papers discussed the 
use of an arsenic-derived compound called atoxyl that showed some effectiveness in 
treating sleeping sickness (Boyce, 1907; Breinl & Todd, 1907). Ehrlich, with German 
chemist Alfred Bertheim (1879 – 1914) and Japanese bacteriologist Sahachirō Hata 
(1873 – 1938), tested modified versions of atoxyl in syphilis-infected rabbits. For 2 years 
there was no sign of success, until in 1909 when they tested the 606th compound. 
Compound 606 was named arsphenamine, and was sold to consumers as Salvarsan by 
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Hoescht AG, a German life sciences company (Ehrlich & Hata, 1909). This became the 
first effective treatment for syphilis with few adverse side effects, and was one of the 
most prescribed drugs for the next 30 years—the first magic bullet. 
Paul Ehrlich’s career as discussed here represents decades of research and the 
dedication to searching through hundreds of potential treatment options. Through his 
persistence, Ehrlich achieved his goal of finding a magic bullet treatment that, when 
injected into the blood, was selectively absorbed by infectious bacteria without causing 
damage to human cells. This need for selectively is still required today, but the modern 
threat of antibiotic resistance has placed significant pressure on researchers to find new 
and effective treatments, and may soon outpace the progress of research in this field. 
Ehrlich set the standard of pharmaceutical development with regards to various drugs. 
Despite the brilliance of Ehrlich’s methodical approach to research, however, the 
approach took far too much time. Screening the effectiveness of individual chemical 
compounds for selective microbial killing activity is a process that has been streamlined 
and made much more efficient with new knowledge surrounding the targeting of bacterial 
cell structures. This is all possible due to a famously “lucky” accidental discovery. 
 
2a. ii. Alexander Fleming, Howard Florey, Ernest Chain, and the discovery of 
penicillin. 
 Many individuals are familiar with the discovery of penicillin. In 1928, Scottish 
physician and microbiologist Sir Alexander Fleming, FRS, FRSE, FRCS (1881 – 1955) 
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was conducting research on various Staphylococcus species—a bacterial genus known to 
cause painful skin rashes, boils, nausea, and vomiting—and had to leave the plates 
exposed to air. On September 3rd after returning from a vacation, Fleming began sorting 
through the plates of Staphylococcus colonies and discovered a large mold growing on 
one of the plates. Mold itself is not unusual when plates are left exposed to air. However, 
what interested Fleming was that around the mold was a clear ‘halo’ wherein bacteria 
would not grow within the halo and those that did were largely clear as a result of lysis, 
or cell killing (Fleming, 1929). 
 
 
Figure 2. Alexander Fleming’s photograph of a bacterial plate growing 
Staphylococci colonies and a Penicillium colony exhibit a clear area (zone of 
inhibition) around the Penicillium mold (Fleming, 1929). 
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As visible in Figure 2, the halo around the Penicillium mold was a result of 
something preventing the bacteria from growing around it. This indicated to Fleming that 
the mold was secreting something that could kill Staphylococcus species. He isolated this 
chemical and called it penicillin, and tested the compound on 7 common infectious 
species at once, showing that the chemical was effective against multiple bacterial types 
(Fleming, 1929). However, Fleming did not believe there was significant potential for 
treating infections, instead emphasizing its potential in the laboratory for isolating 
bacteria resistant to the Penicillium fungus. He tasked his research assistants with the 
purification of penicillin, but ultimately only a crude product could be isolated, and 
Fleming’s 1929 paper suggests possible therapeutic uses without any sense of urgency or 
excitement. He was still interested in the purification of penicillin and provided the 
specific Penicillium strain to anyone who asked for the next 12 years. 
Fleming eventually abandoned hope that penicillin could be isolated, but in 1940 
an Oxford University pathologist, Sir Howard Florey, OM, FRS, FRCP (1898 – 1968), 
and an Oxford University biochemist, Sir Ernest Chain, FRS (1906 – 1979), were able to 
isolate and mass produce the chemical. The two were attempting to discover various 
structural and mechanistic properties of compounds that demonstrated antibacterial 
activity, and among the compounds they decided to test was penicillin. To do this, they 
required large amounts of these antibacterial chemicals, including penicillin, for testing in 
mice, so they approached various British drug manufacturers, but the economic 
instability of World War II made corporations weary of taking many risks. The pair 
devised a method that allowed them to isolate the penicillin, though the process was 
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inefficient considering 500 liters of mold filtrate was needed to produce the amount of 
penicillin needed to inject 4 mice (Chain et al., 2005). 
Recall that Paul Ehrlich had actively sought a chemical of some sort that could 
selectively kill bacteria without harming the host—a magic bullet. Like Ehrlich, Florey 
and Chain relied on animal testing, but utilized a different approach. Ehrlich’s method 
was to infect a mouse and then attempt to dye and kill bacteria without harming the cells 
at whatever dosage he was using, whereas Florey and Chain first injected penicillin to 
ensure there would be no toxicity. Fleming had earlier tested a small dose of penicillin in 
mice to confirm against toxicity, but Florey and Chain injected a larger dose which also 
showed no negative side effects. In the second part of the experiment, the Oxford pair 
delivered a fatal concentration of Streptococcus bacteria to 8 mice, and injected penicillin 
into 4 of the infected mice. Less than 17 hours later, all infected mice without penicillin 
died, as expected, but those with injected penicillin survived and recovered. 
This critical 1940 experiment essentially confirmed the antibacterial behavior of 
penicillin without harming the host, and the significance of Fleming’s discovery was 
suddenly understood. It was first used to treat a patient the following year, and though the 
patient began to make a recovery, there was not enough penicillin to kill all the bacteria 
and he died several days later. Manufacturing the drug at a large scale proved to be a 
challenge, so the Oxford pair traveled to the United States in July of 1941 under the 
sponsorship of the Rockefeller Institution to find a manufacturer for penicillin because 
the United States was less involved in war efforts and were less constrained than English 
companies (Denton, 2013). In 1942, after several companies began production of 
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penicillin, 11 American patients with various bacterial infections were successfully 
treated. It seemed that another one of Ehrlich’s magic bullets had been found. 
The benefits of penicillin in the battlefield became immediately obvious to the 
U.S. War Protection Board who subsequently created a penicillin program involving 21 
companies in 1943 (Bud, 50). Suddenly, all priority was on the mass production of 
penicillin which was then used to treat a majority of war infections from 1943 – 1945, 
and this is sometimes credited with having tipped the scales against Adolf Hitler and his 
forces because fewer Allied men were lost and could rejoin the battlefront. Fleming, 
Florey, and Chain shared the 1945 Nobel Prize in Physiology or Medicine for the 
discovery and development of penicillin. The drug became available to the general 
commercial market and had saturated local drugstores by mid-1945. This marks the 
beginning of the first widespread antibiotic. 
 
2b. Introduction to antibiotics and modes of action. 
Antibiotics are a variety of biomolecules produced by microorganisms that inhibit 
the growth of other microorganisms or kill them. Though new antibiotics are readily 
found in nature, less than 1% can be further developed for clinical application in humans. 
Antibiotic drugs either kill bacteria directly (bactericidal) or inhibit the growth of bacteria 
(bacteriostatic) which will then be destroyed by host immune defenses or excreted. When 
categorizing their effective range of bactericidal or bacteriostatic ability, there are two 
major types of antibiotics; broad-spectrum antibiotics, and narrow-spectrum antibiotics. 
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Broad-spectrum antibiotics can be active against several types or families of bacteria, 
whereas narrow-spectrum usually have limited activity and can only be used to treat one 
or a few bacteria species. The majority of antibiotics used in treatment are produced by 
the Streptomyces genus, which are type of soil bacteria (de Lima Procópio, da Silva, 
Martins, Azevedo, & de Araújo, 2012). The Penicillium mold, which is a type of fungus, 
inhabits a number of surfaces, including various soil environments. Soil teems with many 
small life forms and, as a result, there is much competition for access to nutrients and 
room to grow. Bacteria evolved antibiotics as mechanisms of competition. As previously 
discussed, the benefit of using antibiotics were demonstrated by Florey and Chain in 
1940. Researchers came to realize that the antibiotics were a way of inhibiting the growth 
of bacteria and began examining the relationships between various soil bacteria to find 
new antibiotics to use. Upon initial release, penicillin was a very strong antibiotic and 
used widely, but more antibiotics have since been discovered and are used to clinically 
different types of bacterial infections. 
There are several mechanisms by which various types of antibiotics work, and 
antibiotics are generally classified by the bacterial structures they target. Unlike Paul 
Ehrlich’s quest to find a chemical that completely and lethally stains bacteria, antibiotics 
target various biological structures and metabolic or genetic pathways. While there are 
many classes, the majority of antibiotics inhibit cell wall synthesis, DNA synthesis, or 
protein synthesis (Walsh, 2003). 
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2b. i. Cell wall synthesis inhibition | β-lactam antibiotics 
Antibiotics that inhibit cell wall synthesis fall largely under the category of β-
lactam antibiotics, the majority of which are penicillin derivatives and cephalosporin 
derivatives. β-lactam antibiotics are generally bactericidal, meaning they kill bacteria 
because they disrupt the final stage of bacterial cell walls, which are made of 
peptidoglycan—a type of macromolecule made from amino sugars and short peptides. 
With a weakened cell wall, or without a closed cell wall, a bacterial cell will burst and 
become exposed to its surroundings, meaning it cannot regulate its internal environment, 
and as a result the cell will die. This is what was occurring on Alexander Fleming’s plate 
(Fig. 2). These antibiotics do not negatively affect humans because human cells have 
plasma membranes made of glycolipids (carbohydrates and lipids), and lack 
peptidoglycan structures. 
The class name β-lactam antibiotics comes from a core structure of a four-
membered ring with an amide, as highlighted in the structure of penicillin shown on the 
following page (Figure 3). 
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The β-lactam ring is a very strained structure, which provides its strength as an antibiotic 
because the molecule would prefer to break that ring. The ring binds to penicillin-binding 
proteins (PBPs) anchored in the cell membrane of a bacterium, and this breaks the bond 
between the nitrogen and the carbon that is double-bonded to the oxygen. This reaction 
releases the strain of the 4-membered ring. The molecule remains attached to the PBP 
preventing it from performing its function and disrupting the formation of the bacterial 
cell wall structure. β-lactam antibiotics are usually prescribed as bactericidal, narrow-
spectrum antibiotics that work against gram-positive bacteria, though some exhibit 
bactericidal activity against gram-negative bacteria. Examples of gram-positive bacteria 
include Streptococcus species, Staphylococcus species, and Clostridium species. 
 
Figure 3. Structure of penicillin with the β-lactam 
ring highlighted. 
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2b. ii. DNA synthesis inhibition | Fluoroquinolone antibiotics 
 DNA is necessary for cell growth and cell division, and for a bacterial infection to 
spread—which can spread fast—a lot of DNA replication needs to occur. There are 
various steps involved in the replication of DNA, so there are several possible targets for 
drugs to disrupt this process, but fluoroquinolones and related derivatives are among the 
most commonly prescribed DNA synthesis-inhibiting antibiotics. To separate the DNA 
strands of a bacteria for replication, the topoisomerase IV and DNA gyrase enzymes are 
needed to reduce the strain or tension in the DNA strands. Fluoroquinolones work by 
entering the bacterial cell and binding directly to topoisomerases which causes a 
conformational change (change in shape or structure) that prevents the topoisomerase 
from disconnecting from the DNA. This places such significant strain on the DNA that 
the strand effectively snaps apart. The DNA cannot reattach, and because the cells need 
the genetic material for replication and for producing necessary metabolic molecules, the 
cells die. 
As it so happens, DNA does occasionally naturally become damaged and most 
organisms have evolved mechanisms to repair the damage when needed. If a gap appears 
in the DNA, signals are sent to genetic mechanisms in the bacteria cell and stimulates the 
SOS response—a bacterial genome repair mechanism. However, this repair mechanism 
utilizes what is essentially a lower-quality DNA Polymerase, which creates inaccurate 
copies of the DNA or may even add extra bases in the DNA, leading to fatal additions or 
non-functional genes, which can impair the cell’s functions and even kill it.  
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Fluoroquinolones are generally bactericidal, although some are bacteriostatic, and 
fluoroquinolones can be used against gram-positive and gram-negative bacteria meaning 
they are broad spectrum antibiotics. Fluoroquinolones should not affect humans because 
the bacterial enzymes are sufficiently different from human enzymes and human genome 
mechanisms, but severe side effects of prolonged fluoroquinolone use include tissue 
damage or toxicities of the central nervous system, cardiovascular system, and the 
skeletal muscles (Strauchman & Morningstar, 2012). This is hypothesized to be a result 
of fluoroquinolones acting on mitochondria in human cells. Mitochondria have their own 
genomes which resemble those of bacterial cells, meaning their DNA can be attacked the 
same way bacterial DNA is attacked. Extended fluoroquinolone use can be detrimental as 
a result of inducing mitochondrial dysfunction over time, and suddenly treating 
something as simple as a urinary tract infection can lead to impaired human function if 
antibiotics are misused (Lawrence, Claire, Weissig, Rowe, 1996; Hall, Finoff, & Smith. 
2011; Kalghatgi et al., 2013; Hany, Jörns, & Rustenbeck, 2014). In fact, this has been 
demonstrated as true of several bactericidal antibiotics including beta-lactams. Due to 
this, there have been attempts to address this issue by utilizing antioxidants that 
specifically protect mitochondria from fluoroquinolones (Lowes, Wallace, Murphy, 
Webster, & Galley, 2009). Under proper management and adept professional care, 
however, fluoroquinolones are an effective choice when prescribed for respiratory and 
urinary tract infections, as well as skin infections, bone and joint infections, and typhoid 
infections. 
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2b. iii. Protein synthesis inhibition | Tetracycline antibiotics 
 Proteins are needed for every metabolic process, responding to environmental 
chemical gradients, signaling pathways, binding to various surfaces, regulating gene 
expression, and more. These macromolecules are just as crucial and varied as DNA, and 
serve many critical roles in the cell. Protein synthesis is the final step in the “central 
dogma” of biology. First, DNA is transcribed to create RNA, which then is translated into 
a protein by the ribosomal complex. There are many possible targets in protein synthesis, 
and as such there are a variety of drugs that target various structures and steps of protein 
synthesis in bacteria. Tetracycline antibiotics, in particular, bind to the 30s subunit of the 
bacterial ribosome, which interfere with the RNA binding to the ribosome and can block 
the translation process altogether. A bacterial ribosome consists of a 50s subunit and a 
smaller 30s subunit. Human ribosomes are composed of a larger 60s subunit and a 40s 
subunit, meaning tetracyclines do not interfere with human protein synthesis and are 
therefore safe for clinical use. 
 Tetracyclines are generally bacteriostatic, meaning they stop the growth of 
bacteria, but can also be bactericidal or made more potent with the right serum. Though 
tetracyclines have been shown to be toxic to mitochondria, tetracyclines are generally 
considered non-toxic antibiotics. Clinically relevant doses are generally not concentrated 
enough to cause serious metabolic damage, and because mitochondria ‘live’ within other 
cells, they obtain many of their nutrients from their host cell. Mitochondria produce 
comparatively few proteins and halting protein synthesis within mitochondria might lead 
to a chemical imbalance, but it can be corrected. Tetracyclines are generally prescribed 
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for respiratory tract infections, urinary tract infections, gastrointestinal tract infections, 
skin infections (including acne), and sexually transmitted diseases such as chlamydia, 
gonorrhea, and syphilis.   
 
2c. Threats of antibiotic resistance. 
 With the variety of antibiotics available for clinical treatment of various 
infections, it would seem that bacterial infections are a thing of the past in the modern 
world. Surely Paul Ehrlich hoped this would be the case and hence dedicated his life to 
realizing this vision. However, a chemical solution to a problem controlled by genetic 
factors was not one that could last long. As previously mentioned, antibiotics are 
naturally produced by soil bacteria that compete with each other by secreting chemicals 
that will either kill or halt the growth of other bacteria. Those that can produce more 
potent or more effective antibiotics stand a better chance of surviving and growing, and 
some even produce multiple antibiotics which gives them a wider range of bactericidal or 
bacteriostatic activity. 
Going on the offensive by producing better or more antibiotics is not the only way 
bacteria can compete with each other; bacteria can also defend themselves against various 
antibiotics through several different mechanisms. This is called antibiotic resistance, 
wherein bacteria develop resistance to certain antibiotics that they were previously 
susceptible to. Antibiotic resistance is a genetic response to a chemical threat and is not 
inherently bad because is a natural biological phenomenon. These defenses develop in 
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two ways: 1) through genetic mutations introduced during replication and growth that 
alter the structure of various binding sites, or 2) by acquiring whole genes from an 
external source such as directly from another bacterium, or from the surrounding 
environment. 
In 2014, one study discovered that resistance genes are widespread in non-clinical 
settings, but also in settings with non-detectable antibiotic molecule concentrations 
(Nesme et al., 2014). This study examined metagenomic data sets from various biomes 
such as different types of soil, the ocean, the human gut, Alaskan permafrost, etc. The 
study found that bacteria in relatively more isolated areas possessed transferrable 
antibiotic resistance genes despite having no exposure to human-made antibiotics. 
Though these bacteria were not immediately or constantly exposed to high levels of 
antibiotics, the genes for resistance had made its way through the environment into 
remote regions most humans cannot access. That alone should demonstrate concern for 
the potential impact antibiotic use has and how it may even place humans at greater risk 
of contracting resistant infections. The study also found that bacteria had more 
transferrable resistance genes and accumulated them more quickly in stressful 
environments such as hospitals and the human gut where bacteria may be regularly 
exposed to antibiotics. These concerns are echoed by preceding papers that confirm 
simple antibiotic use is the single most important factor driving antibiotic resistance 
(Aarestrup, Seyfarth, Emborg, Pedersen, Hendriksen, & Bager, 2001; Byarugaba, 2004). 
Antibiotic resistance can develop quickly. In 2016, researchers demonstrated the 
rapid evolution of a wild-type (naturally-occurring) Escherichia coli (Baym et al., 2016). 
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In the span of 11 days, the bacteria evolved to survive concentrations of antibiotic up to 
3,000 times greater than what is normally needed to kill the wild-type E. coli. In natural 
settings where there is an abundance of resistance genes, evolution is more easily 
facilitated, and even faster in healthcare settings due to the significant selective pressure 
of antibiotics. This research article provides the first large-scale observation of the 
adaptive behavior of bacteria as they encounter increasingly higher concentrations of 
antibiotics and evolve to survive in them. To examine how the bacterium Escherichia coli 
adapts to increasingly higher doses of antibiotics, researchers created a 2’x4’ petri dish, 
divided the dish into 9 sections, and saturated each section with different concentrations 
of antibiotics. The two outermost sections of the dish had no antibiotic.  The next inward 
section contained only 3 times more than the minimum clinical concentration normally 
needed to kill the bacteria. Each further inner section represented a 10-fold increase in 
antibiotic concentration (exponential gradient), with the center of the dish containing 
3,000 times more antibiotic needed to kill the bacteria than under normal clinical 
conditions. In the span of 11 days, the bacteria evolved and grew to fill all sections of the 
petri dish. 
 
 28 
 
 
 
 
 
 
It is also important to note that none of the bacteria made the jump from the no-
antibiotic portion of the petri dish to the 1,000x antibiotic concentration section in the 
middle, indicating that this ability to survive greater concentrations of antibiotic is a step-
wise progression that can be prevented by using a strong enough antibiotic or strong 
enough concentration. However, as previously mentioned, using a strong antibiotic for an 
extended period of time can lead to toxic effects within humans as a result of 
mitochondrial dysfunction, and there is the risk that simply increasing the dosage could 
possibly facilitate the step-wise or exponential evolution of resistance in an infectious 
group of bacteria. Additionally, if the resistance spreads, then even more people will have 
to use stronger antibiotics, contributing to a positive feedback loop in which the ultimate 
Figure 4. The four-step trimethoprim MEGA-plate after 12 days. 
E. coli appear as white on the black background. The five stages 
moving inward refer to the 0 MIC units to the 3000 MIC units (3 
– 3x103 = 1000x increase), with the lowest concentration on the 
outer portions of the plate, and the greatest concentration in the 
middle portion of the plate. (Baym et al., 2016). 
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conclusion may be a complete inability to treat infections with resistance to antibiotic 
concentrations too harmful for humans to use clinically. The mere speed at which this can 
occur, as demonstrated by the MEGA-plate in Figure 4, is what has made many so eager 
to study and address this issue before it is too late. 
 
2c. i. How antibiotic resistance develops 
 As previously mentioned, antibiotic resistance develops in two general ways: 1) 
through genetic mutations that alter the structure of various antibiotic binding sites, or 2) 
by acquiring whole genes for new structures or metabolic pathways, and these come from 
an external source such as directly from another bacterium, or from the surrounding 
environment. There are many published reviews on the complex various mechanisms of 
resistance, but generally, these are: 
1. Bacteria can regulate the permeability of their cell wall which restricts antibiotic 
access to target sites, 
2. Bacteria can actively efflux (pump out) the antibiotic from the cell, 
3. Microbes can enzymatically modify the antibiotic into a non-harmful form, 
4. Bacteria can acquire or utilize alternative metabolic pathways to those inhibited 
by the drug, 
5. Bacteria can modify antibiotic targets to prevent binding, and/or 
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6. Bacteria can overproduce the target enzyme to allow normal function which 
counteracts the inhibitory effects of antibiotic binding. 
 
One of the ways antibiotic resistance develops is through mutation, which is 
generally a spontaneous, random alteration of an organism’s genetic code. The bacteria 
with beneficial mutations then pass on these mutations to the following generation of 
bacteria who inherit the new ability or genetic trait. This acquisition of genes from a 
parental source is referred to as vertical gene transfer. Mutation cannot create whole 
genes; as such, mutations generally confer antibiotic resistance by altering the binding 
sites for various antibiotics. For example, bacteria susceptible to β-lactam antibiotics may 
mutate the gene responsible for the PBP structure. Bacteria that normally succumb to 
fluoroquinolone antibiotics may alter the structure of a topoisomerase through random 
mutation. In tetracycline-susceptible bacteria, a mutation could lead to a modified 30s 
bacterial ribosome subunit that may perform as well or slightly less efficiently, but will in 
turn survive antibiotic treatment. These modifications could either make the binding sites 
more likely to bind the respective antibiotic, in which case the mutation is not passed on 
because the cell will be killed, or the mutation could lead to weaker or no antibiotic 
binding which is a beneficial trait that will be passed on so long as the modified structure 
still performs its original function. Alternatively, the structure could be eliminated or 
replaced with a substitutive structure. Another way mutation can confer resistance is by 
promoting the production of enzymes (proteins that participate in various metabolic 
processes and can initiate or catalyze specific reactions) that can inactivate antibiotics or 
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interfere with the binding site. For example, β-lactamases cleave the bond between the 
nitrogen and the carbon that is double-bonded to the oxygen in β-lactam rings, which 
prevents the antibiotic from binding to PBPs and disrupting cell wall synthesis. Yet 
another way that mutation can increase resistance is by preventing the entry of a drug into 
a cell altogether. This is particularly beneficial against antibiotics with targets that are 
within the cell such as fluoroquinolones (DNA) and tetracyclines (protein synthesis). It is 
important to note that mutation it is somewhat limited in that it does not create entirely 
new structures or new genes. 
If the acquisition of genetic material from parental sources is vertical gene 
transfer, then the acquisition of genetic material from non-parental sources is referred to 
as horizontal gene transfer. Horizontal transfer can confer the same types of resistance 
that vertical gene transfer can, but it is particularly advantageous to bacteria in that whole 
genes, including genes for new structures or new ways to get rid of drugs, can be 
acquired this way. There are three general methods of horizontal gene transfer in bacteria: 
transformation, transduction, and conjugation. Transformation is the uptake of short 
fragments of naked, ‘free’ DNA from the surrounding environment. Segments of 
genomic material can often be found floating freely in the environment, and some 
bacteria will naturally take up these genes when they encounter a stressor such as low 
water, high heat, or even chemical stress. For this reason, transformation is a relatively 
common laboratory research method used to alter or modify bacteria in some way, such 
as making bacteria glow (as a result of the acquisition of a whole new gene). 
Transduction refers to the horizontal transfer of genes which are transferred from one 
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bacterium to another through a bacteriophage—a virus that only infects bacteria. When a 
bacteriophage infects a bacterium, its genetic information incorporates itself into the 
bacterial genome, which is then transcribed and translated alongside normal bacterial 
genes. When assembling new bacteriophages, a portion of the host bacterial cell DNA 
may be accidentally packaged with the viral genome. When the new bacteriophage 
infects a different bacterium and injects its genome into that cell with the DNA from 
another bacterial cell, the new DNA becomes incorporated into the bacterial cell. In this 
way, whole genes can be shared between different bacteria. The third method of 
horizontal transfer is called conjugation, and may be the most common method of 
conferring antibiotic resistance. This method requires direct cell-to-cell contact via a 
conjugation pilus, or sex pilus, which is a hollow tube formed by the cell donating the 
genetic material, and this pilus creates a biological tunnel through which genes can move 
from one cell to another. The bacterial cell donating its genetic material does not lose its 
resistance; instead, it creates a copy of those genes and transfers the copies to the cell 
without those genes. 
Horizontal gene transfer can create new structures in cells and provide alternative 
metabolic pathways. One of the most effective antibiotic resistance structures is referred 
to as a drug pump. These essentially pump out a drug if it enters the cell. While drug 
pumps do little against antibiotics that target external cellular structures, antibiotics like 
fluoroquinolones and tetracyclines are more readily pumped out of the cell before they 
can reach their target sites as a result of these structures. This is particularly dangerous 
for individuals who contract bacteria that possess drug pumps, as this greatly reduces the 
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number of possible targets for which the antibiotics can act on. This is spread quickly and 
easily, posing a serious risk to global health and treatment of disease. 
 
2c. ii. How human use of antibiotics contributes to resistance. 
Why does antibiotic resistance matter? Here’s a hint: multidrug-resistant bacteria 
are also commonly referred to as ‘superbugs’—a term more often used in news media 
because it requires significantly less effort to say and is a catchier name. There have 
already been several waves of extremely resistant pathogens, or superbugs, one of the 
most recognizable being MRSA, or methicillin-resistant Staphylococcus aureus. These 
superbugs are resistant to the majority of antibiotics and some already have developed 
resistance to all available antibiotics. For example, early in September of 2016, a Nevada 
woman in her 70s died after contracting carbapenem-resistant Enterobacteriaceae 
(CRE)—a bacteria that generally causes digestive tract infections. Physicians and 
researchers tested the bacteria against 26 different antibiotics, and it was resistant to each 
one, including a drug named Colistin that is used as a potent, last-resort treatment 
because it causes significant kidney damage (Chen, Todd, Kiehlbauch, Walters, & 
Kallen, 2017). This particular pathogen is becoming a more pressing issue. Prior to 2012, 
there were 25 reported cases of this bacteria in the US. In 2012 alone, there were an 
additional 12 cases of infection by this pathogen.  
Recall that penicillin was made available to the general public in mid-1945. 
However, in the same paper that Alexander Fleming published announcing penicillin, he 
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also described a group of bacteria that seemed to be unaffected by the antibiotic 
(Fleming, 1929). In 1940, English biochemist Sir Edward Penley Abraham, CBE FRS 
(1913 – 1939) and Ernest Chain—the Oxford biochemist who worked with Howard 
Florey to mass produce penicillin—recorded their discovery of an enzyme isolated from 
bacteria that was capable of destroying penicillin (Abraham & Chain, 1940). Before 
penicillin was mass produced for commercial use, a natural defense against it was found, 
prompting Alexander Fleming to warn of antibiotic resistance in his 1945 Noble Prize 
acceptance speech (Fleming, 1945). The last thing he relayed in his speech was the 
following hypothetical scenario as an example of how antibiotic resistance may easily get 
out of hand: 
 
Mr. X. has a sore throat. He buys some penicillin and gives himself, not enough to 
kill the streptococci [a bacterium] but enough to educate them to resist penicillin. 
He then infects his wife. Mrs. X gets pneumonia and is treated with penicillin. As 
the streptococci are now resistant to penicillin the treatment fails. Mrs. X dies. 
Who is primarily responsible for Mrs. X’s death? Why Mr. X whose negligent use 
of penicillin changed the nature of the microbe. Moral: If you use penicillin, use 
enough. (1945) 
 
This is a situation of our own making. Physicians use antibiotics, and sometimes 
an antibiotic is not strong enough to fight an infection, or not enough is used. Antibiotic 
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resistance is globally problematic for human health because it means that bacteria 
become less susceptible to current drug routines. One of the more visible upstream causes 
is the gross over-prescription of antibiotics; some physicians prescribe up to three times 
as many antibiotics as their counterparts (Fridkin et al., 2014). Often a physician will 
prescribe a broad-spectrum antibiotic to cover as many bases as possible, so to speak. 
This is not uncommon especially because not everyone has the time, or wants, to wait for 
a lab diagnosis of an infection. Other patients convince themselves antibiotics are the 
appropriate response to illness, even in cases of a mild, self-limiting infection, and are 
persistent to the point of harassing physicians for antibiotic prescriptions. This may be 
due to a lack of effective communication of the risks or a gap in the education. Physicians 
who overprescribe antibiotics may not be convinced of their contribution to antibiotic 
resistance, or may care less about educating incessant, ignorant patients and instead 
prioritize the convenience of prescribing a broad-spectrum antibiotic. Some physicians 
have pushed back on this reasoning, claiming there is little to no harm in prescribing an 
antibiotic cocktail to a patient who is visibly infected and for whom a laboratory 
diagnosis can be obtained the following day (Hoffman, 2012; Ingram, Seet, Budgeon, & 
Murray, 2012). Recall that bacteria have evolved ways to combat antibiotics, meaning 
that administering a particular antibiotic while the rest succumb to the same drug makes it 
easier for the surviving bacteria to grow and multiply (reduced competition), and further 
spread this resistant character. Suddenly, as Fleming illustrated, human use of antibiotics 
has “changed the nature of the microbe” and stronger, perhaps more targeted antibiotics 
are necessary when treating a patient for an infection. Without aggressive action to 
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compensate for this issue, existing drug routines may become obsolete. In developing 
countries, a significant number of infections are becoming increasingly multi-drug 
resistant as a result of similar misuse in field medicine (Byarugaba, 2004). Overuse 
accelerates resistance. 
It is also important to note that the livestock industry uses antibiotics to minimize 
infections in animals kept in close quarters, and are also often overused due to their 
secondary benefit of growing animals larger at a faster pace. As a result, resistance can 
further develop within livestock and downstream of the growth process including 
livestock consumption. Some bacteria have been isolated from food animals and display 
resistance to last-resort antibiotics like carbapenems (Fischer et al., 2012; Fischer et al., 
2013). However, the scope of this paper is more interested in the healthcare setting, and 
will thus not delve further into livestock antibiotic use. 
 Overuse and misprescription, the most significant contributing factors to the 
spread of antibiotic resistance, are not limited to the doctor’s office. Individual consumers 
need to be aware of how general misuse accelerates this issue. Taking antibiotics for viral 
infections such as the cold or the flu will not cure the infection; instead, the antibiotics 
may target bacteria in your body that is beneficial or at least not disease-causing, and 
promote resistance in otherwise harmless bacteria, which can then be spread through 
vertical or horizontal gene transfer. Taking another person’s antibiotics and taking the 
wrong antibiotics also contribute in this manner. Another common way that consumers 
perpetuate antibiotic resistance is by not completing a prescription for antibiotics, instead 
choosing to stop consuming antibiotics when symptoms disappear. The risk of this line of 
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thinking is that the antibiotics may have killed most of an infection, at which point most 
symptoms will disappear, but does not kill all of them. As a result, the consumer falsely 
believes that all infectious bacteria are killed, and dispose of their antibiotics. Not only do 
the remaining bacteria likely possess resistance genes which can then be passed on to 
other bacteria via gene transfer, but the unused antibiotics then end up in the waste stream 
where more bacteria can be exposed to the antibiotics in concentrations that are too dilute 
to kill most, instead promoting tolerance to the treatment. 
 The solution seems clear then: use antibiotics less frequently for less serious 
infections, take antibiotics only when prescribed, and complete the full prescribed drug 
routine so as not to introduce antibiotics into the waste stream. While this appears to be a 
simple fix to a worldwide problem, this is flawed thinking as a result of one major factor: 
the bacteria generally still retain their resistance genes, so antibiotics will still need to be 
prescribed for a variety of infections to prevent the further spread of these genes. While 
antibiotic traits can be lost, the process of losing a gene is much slower than that of 
gaining a gene. Currently there are not many widespread, inexpensive, and accurate ways 
to determine the level of resistance a particular bacterium may have or what antibiotics it 
may be susceptible to. This is not a consumer problem so much as it is a healthcare 
problem. 
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2c. iii. How can we address antibiotic resistance? 
The next step is to look at the current methods of addressing the problem. Due in 
part to the groundwork laid by Paul Ehrlich, there is still much funding being poured into 
traditional drug discovery. The PEW Charitable Trusts is an independent, non-profit, 
non-governmental entity that creates an annual report based on publicly-available 
information provided by studies pending approval of drugs. According to the PEW 
Charitable Trusts, there are 41 drugs in development as of March 2017. Generally 
speaking, only about 20% of new drugs are approved for use, so only about 5 of these 
drugs may statistically become commercially available (Hay, Thomas, Craighead, 
Economides, & Rosenthal, 2014). To compound this somewhat disheartening reality, the 
antibiotic discovery pipeline is quickly dwindling. As a result, some have focused their 
efforts on finding new target structures to create novel antibiotics (McDevitt, Payne, 
Holmes, & Rosenberg, 2002; Rao, De Waelheyns, Economou, & Anné, 2014; Culp & 
Wright, 2016). However, very few have come to market, including Zyvox™ (linezolid; 
used to treat skin infections and pneumonia), Cubicin™ (daptomycin; used to treat skin 
and tissue infections), and Sivextro™ (tedizolid; used to treat MRSA skin infections). For 
some, this may indicate that the end of the chemical era in the treatment of bacterial 
infections is coming to an end, unless there is a way to repurpose existing drugs or 
somehow reverse the acquisition and spread of resistance genes. 
It seems there has already been some success in addressing this issue for some 
infections. One approach is to administer an antibiotic along with an anti-resistance 
compound to minimize the risk of developing resistance. For example, one commercially 
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available drug called Augmentin® which is used to treat a variety of infections including 
sinusitis, pneumonia, ear infections, skin infections, and urinary tract infections, among 
others. It is a combination of amoxicillin, which is a type of penicillin (β-lactam), and 
clavulanate potassium. The function of clavulanate potassium should be somewhat 
obvious from the other drug it is combined with, which is a β-lactam antibiotic; 
clavulanate potassium deactivates β-lactamases which are enzymes that cleave the β-
lactam ring bond between the nitrogen and the carbon with a double-bonded oxygen. This 
dual action makes amoxicillin-resistant cells susceptible to amoxicillin again which 
provides the combination drug its wide breadth in treatment. However, if the structure of 
the PBPs that β-lactam antibiotics would bind to is altered, the effectiveness of 
Augmentin® is less than if the bacteria simply secreted an enzyme that the clavulanate 
potassium could deactivate. Additionally, resistance to Augmentin® has already been 
recorded (Oteo et al., 2008; Rahnama’i, Wagenvoort, & van der Linden, 2009). 
Regardless, the improved effectiveness of a combination drug provides some hope to the 
rapidly vanishing antibiotic discovery pipeline. 
Despite the emergence of resistance to combination drugs like Augmentin®, there 
have been attempts to direct their use in a way that minimizes the development and 
spread of resistance (GlaxoSmithKline, 2006). This has been incorporated into a strategic 
approach referred to as antimicrobial stewardship programs. These are coordinated 
programs designed to improve and inform the practice of prescribing antibiotics. The 
Centers for Disease Control and Prevention (CDC) together with two other national 
agencies have created a set of guiding principles and general techniques after which other 
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antimicrobial stewardship programs can be modeled (Centers for Disease Control and 
Prevention, National Center for Emerging and Zoonotic Infectious Diseases & Division 
of Healthcare Quality Promotion, 2017). The CDC recommends that these methods and 
standards be adopted by all hospitals, long-term care facilities, emergency surgical 
centers, dialysis centers, and private practices. 
 
2c. iv. Antibiotic resistance diagnosis. 
 As previously mentioned, a critical factor in the slowing or reversing of antibiotic 
resistance is the need to use antibiotics more purposefully. This means that the general 
practice of blindly prescribing broad-spectrum antibiotics or antibiotic cocktails needs to 
end. To do this, physicians need some way to identify which pathogen is responsible for 
an infection, and furthermore need to know which antibiotics the pathogen is resistant to. 
Generally speaking, a physician can interpret symptoms and vital statistics to determine 
which bacteria or group of bacteria are responsible for a bacterial infection. However, 
since a variety of bacteria can stimulate similar or identical symptoms, physicians rarely 
rely solely on medical interpretation and instead opt for antibiotic susceptibility testing 
(AST). 
Laboratory testing is generally a phenotypic AST method that relies on a sample 
of bacteria collected from an infected area which can then be grown in a medium, 
typically an agar tube, agar plate, or liquid broth, and then can be physically 
characterized by experienced microbiologists who then inform the physician. In a 
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laboratory, a common way to test which antibiotics an infection may be resistant to is to 
soak small disks in various antibiotics at clinically relevant concentrations and place them 
onto a freshly spread agar plate. The plate is covered and left undisturbed for a period of 
time to allow bacterial colonies to grow and cover the plate, and then the plate is checked 
for the presence of halos. This is called a Kirby-Bauer disk diffusion assay which can be 
used to test multiple antibiotic compounds at once (Jenkins & Schuetz, 2012). Recall that, 
as on Alexander Fleming’s plate (Figure 2), a clear area around a substance indicates that 
the substance (antibiotic) is capable of killing the bacterial cells. 
 
 
 
 
 
Figure 5. Kirby-Bauer antibiotic resistance assay on a 
MRSA culture. (Zimmerman et al., 2012). 
 42 
 
In Figure 5, the white disks, known as Kirby-Bauer disks, have been soaked in various 
antibiotics and left on the plate to allow the MRSA culture to grow and respond to the 
antibiotics (Zimmerman et al., 2012). The presence of the halos, known as zones of 
inhibition, indicate antibiotic activity against the bacteria, or the bacteria’s susceptibility 
to the antibiotic. The disks with no halo around them indicate that the MRSA culture is 
unaffected by those antibiotics because it possesses resistance mechanisms against those 
antibiotics. Again, several days may be needed to confirm which antibiotics are effective 
against a pathogen. However, as implied in Figure 5, if an antibiotic cocktail does not 
contain any bactericidal or bacteriostatic antibiotics, the infection will not improve and 
antibiotic resistance may spread in addition to harming an individual’s microbiome and 
possibly introducing avoidable mitochondrial toxicity. In the case of MRSA which can 
often be a fatal infection, there may not be enough time to wait for a positive diagnosis or 
susceptibility treatment. 
A modified form of the Kirby-Bauer disk diffusion assay is to use E-tests in place 
of the antibiotic soaked disks (Jorgensen & Ferguson, 2009). E-tests are strips that are 
loaded with a gradient of concentrations of individual antibiotics, producing a zone of 
inhibition on a bacterial plate much like in the disk diffusion assay, allowing physicians 
to limit the dosage or strength of antibiotic needed for antibiotic treatment of an infection. 
While this sounds promising, E-test strips cost several USD per individual strip, and each 
strip only contains one antibiotic, so when testing for susceptibility multiple strips may be 
needed. This is less than ideal, so current practice is to reserve this diagnostic method for 
use when a pathogen’s identity is certain and minimal tests are needed. This test is also 
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limited by the amount of time needed for bacteria to grow, but the results are visible at a 
glance and can quickly inform physicians who wish to limit clinical strength of 
prescription antibiotics. 
Though bacteria can replicate rapidly, a typical phenotypic AST usually requires 
24-48 hours of uninterrupted growth to ensure the formation of mature colonies that can 
be further examined under microscopes or characterized using a number of other tests. 
This is generally why in modernized healthcare it may take several days to learn the 
results of a throat or ear swab or blood test, and in this time physicians tend to prescribe 
broad-spectrum antibiotics or antibiotic cocktails to help alleviate some symptoms with 
the hope of possibly getting a head start on treatment (Hoffman, 2012). In emergency 
situations, however, this is not an option to consider, for the sole reason that testing may 
require more time than is available to the patient. In resource-limited settings, not only 
may lab access be difficult, but there may be unreliability in the ability to maintain 
conditions for growth and sterile technique. Additionally, with increasing time between 
sample collection and reporting results to patients, the likelihood of patients seeking 
treatment decreases (Pop-Eleches et al., 2011; Taber, Leyva, & Persoskie, 2015). This 
inefficient step is the first that needs to be addressed in diagnosing an infection. Reducing 
the time needed between obtaining a sample and tailoring a custom antibiotic treatment 
plan is important to optimize successful treatment and minimize the risk of antibiotic 
resistance. 
In clinical diagnosis, physicians more greatly value the phenotypic results of 
ASTs as the phenotypic response is theoretically identical to the response of the pathogen 
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in question, in which case the results directly translate to prescribed treatment. Following 
this reasoning, the primary development in ASTs have focused on making phenotypic 
ASTs more rapid and accurate (van Belkum et al., 2013). The field of microfluidics has 
risen to meet this challenge, and has produced a number of tests that can work with 
incredible accuracy and increasingly miniscule amounts of fluid, as the name may 
suggest (Reece et al., 2016). 
Microfluidics has made it possible to obtain phenotypic results in as little as 1 – 3 
hours through a category of tests known as flow cytometers or lateral flow assays, in 
which there is no need for a bacterial culture (Choi et al., 2013; Hou et al., 2014; Kim, 
Cestellos-Blanco, Inoue, & Zare, 2015). One study published in August of 2017 claims to 
have created a method that can detect susceptibility in less than 30 minutes (including 
sample preparation, loading, and processing) using minute concentrations of bacteria 
(Baltekin, Boucharin, Tano, Andersson, & Elf). Flow cytometers and lateral flow assays 
generally work by moving cells through a small opening using a small amount of fluid. 
The small opening allows for the isolation of small amounts of cells or even single cells 
which can then be analyzed by measuring a change in electrical conductivity or by the 
detection of light as emitted or scattered by a bacterial cell. A computer analyzes these 
results and can range in complexity from simple quantification tests to, as mentioned 
here, susceptibility tests. This sounds as though the problem is solved, but the biggest 
barrier to their implementation is the cost of individual tests. These tests range in cost 
depending on the complexity of the analyses, require access to reliable electricity, are not 
always easily portable, depend on the use of precise mixtures of costly fluids and buffers, 
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and many have limited shelf life. Evidently, phenotypic ASTs are not yet the optimal 
choice for rapid, point-of-care diagnosis of antibiotic resistance. 
Genotypic ASTs are generally faster than most traditional methods of laboratory 
detection, providing results in as little as 108 minutes instead of days (Fredborg et al., 
2015). Genotypic ASTs utilize common genetic research techniques such as DNA 
hybridization in which a known genetic sequence can be ‘tagged’ with a fluorescent 
probe, or use polymerase chain reaction (PCR) to rapidly amplify small amounts of 
bacterial genome and detect resistance genes with DNA fingerprinting (gel 
electrophoresis). There are several issues with relying on genotypic ASTs. In the case of 
multiple infections in a single patient, there is a risk of false-positive results due to the 
contamination of specimens. Additionally, clinical diagnosis of genotypic ASTs much be 
cautiously interpreted because organisms in an individual’s normal microbiota may 
display matching genes. Genotypic ASTs are also of somewhat limited use to physician 
because possessing resistance genes does not necessarily mean that the bacterium is 
resistant to an antibiotic; as such, bacteria with resistance genes may not necessarily 
express any or all resistance genes, and in reality can be susceptible to an antibiotic 
weaker than what a genotypic AST might indicate (van Belkum et al., 2013). Previously 
it was discussed that antibiotics can cause mitochondrial toxicity, so wherever a weaker 
antibiotic can be used, it is advantageous to do so to minimize undesirable side effects. A 
genotypic test requires knowledge of the genes that need to be identified in a sample, so 
in the case of an unknown resistance gene or of bacteria with many resistance genes, 
most genotypic tests are not an optimal choice. This means that genotypic ASTs can only 
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detect the presence of resistance genes, but cannot inform true susceptibility. Perhaps it is 
time to focus on improving genetic ASTs. The potential drawbacks of existing genotypic 
ASTs suggest the field is ripe for disruption and innovation. 
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3. CRISPR 
3a. Introduction to CRISPR 
In 1987, a Japanese molecular biologist named Yoshizumi Ishino was researching 
the iap gene which codes for a metabolic protein in Escherichia coli bacteria. In an 
attempt to uncover mechanisms that may affect its expression, Ishino and his fellow 
researchers decided to sequence genetic regions near wherever the iap gene was found. 
The last paragraph of Ishino’s journal publication reads, 
 
“An unusual structure was found in the 3’-end flanking region of iap. Five highly 
homologous sequences of 29 nucleotides were arranged as direct repeats with 32 
nucleotides as spacing. [. . .] Well-conserved nucleotide sequences containing a 
dyad symmetry, named REP sequences, have been found in E. coli and 
Salmonella typhimurium and may act to stabilize mRNA. A dyad symmetry with 
14 nucleotide pairs was also found in the middle of these sequences but no 
homology was found between these sequences and the REP sequence. So far, no 
sequence homologous to these has been found elsewhere in procaryotes, and the 
biological significance of these sequences is not known.” (Ishino, Shinagawa, 
Makino, Amemura, & Nakata, 1987). 
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Repetitive extragenic palindromic (REP) sequences are what Ishino was looking 
for when his team decided to look at the genetic regions surrounding the iap gene, as they 
regulate gene expression (Stern, Ames, Smith, Robinson, & Higgins, 1984). However, 
Ishino evidently found something he did not recognize in some of these REP sequences. 
As Ishino described, these were short, nearly-identical DNA segments that we found 
together with regular spacing between each of the segments. The dyad symmetry Ishino 
mentioned means that the genetic material can be read the same back and forth - much 
like the words ‘radar’ or ‘kayak,’ both of which are palindromes. The purpose and 
function of these never-before-described genetic structures remained a mystery, and were 
considered largely unremarkable for a short while.  
Similar unusual genetic structures were soon described in a wide range of other 
prokaryotic organisms. In 1992, a Spanish microbiologist named Francisco Mojica (1963 
– present) studied these structures in salt-loving archaebacteria and recognized that the 
structures followed certain patterns and exhibited shared features, indicating that 
something more intricate was responsible for these seemingly highly-organized, yet 
randomly-placed sequences being observed in many prokaryotes inhabiting many 
different environments. By the turn of the 21st century, these structures were so 
commonly found that there needed to be a term for researchers to more easily 
communicate findings about them, so in 2002 a team of Dutch researchers headed by 
Ruud Jansen at Utretch University published a paper labeling these structures as 
CRISPRs, which stands for clustered, regularly interspaced short palindromic repeats 
(Jansen, Embden, Gaastra, & Schouls, 2002). Curious as to why so many different 
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bacteria would exhibit similar patterns of foreign genetic storage, Mojica and his team 
delved further. Genetic technology had rapidly advanced at this stage, so Mojica’s 
genomic research revealed that the sequences were homologous or analogous to portions 
of bacteriophage genomes (Mojica, Diez-Villasenor, Garcia-Martinez, & Soria, 2005). 
Bacteriophage are viruses that specifically attack bacteria, but it wasn’t clear why the 
bacteria would be storing the genetic information of their attackers. Mojica realized that 
this meant the bacteria were somehow storing portions of viruses they had encountered 
and were utilizing this to recognize the viruses in future infections – essentially a 
prokaryotic adaptive immune system. Most of these CRISPR sequences demonstrate an 
ability to fold into stable DNA or RNA structures and act as regulatory factors for protein 
synthesis or gene expression. In 2006, another group theorized the hypothetical way in 
which CRISPR worked, and the following year a separate group experimentally 
demonstrated that bacteria incorporated the bacteriophage genome into their own genome 
after successfully fighting off an infection (Makarova, Grishin, Shabalina, Wolf, & 
Koonin, 2006; Barrangou et al., 2007). In 2008, researchers from the University of 
Illinois discovered that CRISPR can target DNA and can naturally play a role in limiting 
horizontal gene transfer (Marraffini & Sontheimer, 2008). 
CRISPR-Cas9 is the name of the genetic mechanism that specifically targets 
DNA. The complex comprises of an RNA-guided endonuclease, Cas9, which creates a 
break in the double-stranded DNA structure. A single-guide RNA (gRNA) can help the 
Cas9 target specific loci on the DNA based on the sequence of the gRNA. When a 
bacteriophage infects a bacterium, the Cas9 catalogs small genomic segments of the 
 50 
 
invader’s genome into the bacterial cell’s own genome. Upon future infection of the same 
or similar bacteriophage, the CRISPR-Cas9 mechanism can effectively recognize the 
genetic material of the invader and cleave the genome to counter the infection. 
Since the actual mechanism of CRISPR is less important to the scope of this 
paper, it will not be covered in extensive detail, but several components and steps of the 
mechanism were progressively uncovered in the following years leading up to the real 
scientific breakthrough: in 2013, a team comprised mostly of Harvard researchers led by 
Chinese-American biochemist Feng Zhang (1982-present) demonstrated the use of 
CRISPR-Cas9, a versatile version of CRISPR, in genome editing (Cong et al., 2013). The 
potential for using CRISPR was suddenly broadened, and, as a promising new method of 
genome editing, many were quick to conduct research regarding its use. Only five years 
have passed since the publication of this technology, and it has already been used to 
remove malaria from mosquitos, repair and reverse retinal degradation in mice 
(blindness), treat muscular dystrophy in a mouse with the potential for human 
application, and reactivate genes in human brain cells to counteract an intellectual 
disability caused by Fragile-X Syndrome (Gantz et al., 2015; Bassuk, Zheng, Li, Tsang, 
& Mahajan, 2016; Nelson et al., 2016; Liu et al., 2018). Indeed, the speed at which this 
technology is developing is threatening to outpace the necessary discussions surrounding 
its implementation. Many of the ethical discussions around genome editing have already 
been covered, as genome editing is not a relatively new technology. CRISPR refines and 
simplifies the previously more precarious option of gene therapy by making genome 
editing more accessible and more precise, and it is comparatively very cost efficient. 
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3b. Clinical application of CRISPR 
3b. i. CRISPR and detecting antibiotic resistance. 
CRISPR-Cas9 is the genetic machinery that can be used for DNA editing, and is 
the form that will likely dominate media headlines for years to come. While this can be 
used to individually alter bacterium and perhaps edit out antibiotic resistance genes and 
confer susceptibility genes in their place, this seems somewhat unrealistic and may place 
unnecessary strain on an individual patient and the individual’s microbiota. Instead, there 
is an opportunity to use a different form of CRISPR to enhance existing antibiotic drug 
therapy. 
CRISPR-Cas13a is comparable to CRISPR-Cas9 in its use for genome editing; 
however, while CRISPR-Cas9 alters DNA, CRISPR-Cas13a operates on RNA. This is 
advantageous because changes to RNA are less permanent and therefore potentially less 
dangerous than editing DNA. One paper published in April of 2017 has recently gained 
significant interest for their development of a CRISPR-Cas13a mechanism that has 
proven to be the most sensitive AST yet with attomolar sensitivity—that is 1x10-18 moles 
of RNA per liter of liquid—and it is classified as a nucleic acid diagnostic (genotypic) 
AST (Gootenberg et al.). The CRISPR-Cas13a has two RNA cleaving capacities. First, it 
is able to cleave RNA that matches the sequence of the customized tracrRNA and gRNA. 
Once the Cas13a complex finds and cleaves its target RNA, its second cleaving activity is 
activated. This cleaving is non-specific and far more generic, cleaving any nearby RNA 
in the cell or in a given reaction mixture. In 2016, the Cas13a complex by itself was 
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found to be capable of cleaving at least 1x104 times as many general RNA for just 1 
target RNA cleaved (East-Seletsky et al.). This cleaving activity produces a strong signal 
that makes it a powerful diagnostic tool with a potential to detect even trace presence of 
antibiotic resistance, with picomolar sensitivity—that is 1x10-12 moles per liter of liquid. 
Gootenberg et al. took this naturally existing sensitivity and sought to enhance it 
for diagnostic use, and upon success dubbed the system SHERLOCK (Specific High-
Sensitivity Enzymatic Reporter UnLOCKing) (2017). To obtain the attomolar sensitivity, 
Gootenberg et al. utilized a genetic technique known as recombinase polymerase 
amplification (RPA) which is comparable to PCR. Traditional PCR requires cycling 
between high and low temperatures to produce many copies of genome segments, 
whereas RPA uses enzyme mixes that can perform a similar genomic amplification 
within a temperature range of 37°C – 42°C (normal human body temperature is 
approximately 37°C). This means that no expensive machinery is required to precisely 
cycle an enzyme mixture between various temperatures, reducing both the cost and the 
reaction time, and this lends the ability to run many simultaneous diagnostic tests. The 
RPA increased the concentration of the target RNA in solution, thereby increasing the 
level of CRIPSR-Cas13a target RNA-specific cleaving activity. This cleaving activity 
also enhanced the level of non-specific RNA cleaving activity. To utilize this as a 
diagnostic tool, Gootenberg et al. attached a fluorescent probe to the tracRNA that, when 
cleaved, activates the fluorophore and produces a visible fluorescent signal, and this 
activation occurs when the Cas13a cleaves it during non-specific cleavage (2017). The 
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researchers were able to successfully use SHERLOCK to detect minute concentrations of 
Zika virus and Dengue virus. 
Does this mean that CRISPR-Cas13a can be used as a diagnostic tool to combat 
antibiotic resistance? Yes—and no. It is able to detect the presence of antibiotic 
resistance genes, and at incredibly small concentrations which is a critical improvement 
in early diagnosis. CRISPR-Cas13a solves the issue of signaling the possession of genes 
by instead indicating active transcription, and therefore existence, of resistance 
mechanisms within a cell. However, at the time of writing, SHERLOCK suffers from 
some of the same issues as existing genotypic ASTs: it does not inform physicians of 
phenotypic action, cannot provide accurate quantification of resistant bacteria, and cannot 
indicate antibiotic susceptibility thresholds on its own. Additionally, the increased 
sensitivity of the test places increased pressure towards practicing sterile technique, 
because even the slightest contamination may indicate a false positive. This whole paper 
has led up until this point, and suddenly it seems as though it was all for naught. But not 
so: the critical factor identified early on in this paper was the inability or inefficiency of 
testing for antibiotic resistance. This technology indicates what is now achievable, and 
the increase in detection sensitivity with shortened detection time marks the beginning of 
combating antibiotic resistance. Specifically, it shortens the time between sample 
collection, diagnosis, and treatment prescription, with incredible accuracy so as to allow 
patients to obtain a tailored plan within a short period of time at extremely low cost. This 
alone may significantly reduce the need for broad-spectrum antibiotics and antibiotic 
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cocktails, and may potentially replace existing phenotypic tests for pathogen 
characterization. 
The authors of the SHERLOCK paper also claim they were able to lyophilize 
(freeze-dry) both the CRISPR-Cas13a and the RPA enzyme mixture for reactivation at a 
future time. This is appealing not only for reducing the need to synthesize new 
SHERLOCK components, but also indicates that it can easily be stored for an extended 
amount of time with minimal degradation which demonstrates improved shelf life. These 
confer to it a potential advantage in healthcare settings, and a clear advantage in resource-
limited settings where proper storage and long shelf life can be challenging. Phenotypic 
ASTs remain the best chance at identifying antibiotic resistance, but clinical application 
of CRISPR is still in its infancy. Because it is a CRISPR-based diagnostic system, part of 
its value lies in the fact that it can be quickly customized with ease for use in various 
geographical regions or new pandemic diseases, or can be used to determine the presence 
of superbugs before they arise in healthcare settings. Such a technology may prove 
invaluable in the fight to curtail the progress of antibiotic resistance. This alone may not 
be enough, however, and it is worth discussing where CRISPR technology may lead. 
 
3b. ii. CRISPR and potential antibiotic therapy. 
 The appeal of a CRISPR-based treatment has driven recent research and 
discussion surrounding its implementation in a familiar form. Specifically, one of the 
more hyped concepts in scientific and news media is the idea of the CRISPR Pill. With 
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knowledge of CRISPR’s customizability, there is hope in the scientific community that a 
CRISPR-based antibiotic may one day replace the reliance on biochemical antibiotics. 
A 2014 study reported the manufacture of bacteriophages that carried DNA 
similar to the antibiotic resistance genes (Citorik, Mimee, & Lu). When these phages 
infected bacteria, cells registered the DNA as foreign invader genes and the inherent 
CRISPR-Cas system in the bacteria attacked its own genome. This resulted in the killing 
of bacteria with only the bacterial resistance genes, and left all other cells lacking the 
genes untouched. If there were unharmed bacteria following this initial treatment, this 
was due to the lack of resistance genes and could be effectively treated with existing 
antibiotics. This alone demonstrates a far greater effect than detection alone, as this 
CRISPR treatment enhances existing antibiotics or circumvents them altogether. 
However, phage therapy still carries its risks, including the potential to cause 
cancer if an oncogenic bacteriophage is used, or if the immune system recognizes the 
foreign invader and mitigates the potential desired impact of the treatment (Loc-Carrillo 
& Abedon, 2011). Additionally, bacteriophages are specific with regards to which 
bacteria they infect, and searching for an optimal vehicle for CRISPR-based treatment for 
specific bacteria may prove a costly and time-consuming task that hinders the efficiency 
of the treatment. However, this may aid in minimizing mitochondrial toxicity. 
Another challenge to CRISPR-based phage therapy is that bacteriophages 
typically degrade in the stomach. To ensure optimal distribution transport of the 
bacteriophages, if taken orally instead of injected, the bacteriophage would need to be 
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coated in a lipid layer which can then attach to specific cells where the bacteriophage 
could then infect those cells. This seems too unwieldy, so MIT scientists proposed and 
published a proof-of-concept in which they demonstrated the creation of lipid 
nanoparticles that could cloak CRISPR-Cas mechanisms without the need for viruses 
(Yin et al., 2017).  These lipid nanoparticles are able to fuse with or pass through cell 
membranes and deliver the CRISPR-Cas machinery directly into the cell. The researchers 
dubbed this RNA medicine. There is much to be seen in the way of development with 
this technology, but bypassing the need for use of a bacteriophage possibly inches 
progress closer to the formulation of an actual magic bullet. 
These are baby steps, but they are giant baby steps towards a future that will see a 
radical shift in the approach to medicine. There is yet a long way to go, and the young 
age of this powerful technology should warrant some caution surrounding its use, but so 
far it appears that results are hopeful. Perhaps one day, patients will receive instantaneous 
results diagnosing infections and several minutes later receive custom medication that 
specifically targets pathogens leaving the existing microbiota unharmed. 
 
3c. A CRISPR cautionary case. 
Despite the optimism surrounding the use of CRISPR-Cas9 as a potential basis for 
medical treatment and genetic remedy, there ought to be caution regarding its healthcare 
implementation. Its primary hurdle is that the technology’s young age means long-term 
effects must still be carefully monitored. It was previously mentioned that a team of 
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scientists reversed blindness in mice using CRISPR-Cas9, the DNA editing CRISPR 
mechanism (Bassuk et al., 2016). At the time of writing, this study has been cited nearly 
70 times. In August of 2016, another team, including the leading author of the previous 
study, used a similar method to successfully reverse the effects of retinitis pigmentosa: a 
related genetic disease that causes a loss of vision (Wu et al., 2016). This was reported as 
a success and additional hope was lent to the potential use of CRISPR as a treatment for 
eye disorders. Approximately 1 year later, however, the authors of this second study 
submitted a letter to the editors of the Nature Methods journal (Schaefer et al., 2017). In 
this letter they revealed that they observed more than 2,000 undesired mutations, some 
cancerous, in each of the mice they had treated, which is certainly not an insignificant 
number. 
The immediate reaction of some media was to suddenly claim that it was far too 
risky a technology to use, and that CRISPR was dead. Much of the scientific community 
was appalled and confused with the team’s reporting which seemed to stand at odds 
against the history of CRISPR technology. In response to this potentially devastating 
letter, many rushed to discredit it, focusing on the team’s small sample size, their method 
of choice for delivering CRISPR to target cells, and even doubted whether it was a peer-
reviewed study (Lareau et al., 2017). This illustrates 2 things: 1) the hostility of some in 
the scientific community towards contradictory findings in CRISPR research, and 2) that 
more research needs to be conducted to explore the technology before extensive use in 
humans. As previously mentioned, the study in which scientists reversed blindness in 
mice has been cited nearly 70 times at the time of writing. If this treatment has similar 
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downstream effects as the retinitis pigmentosa treatment, a large number of studies have 
cited a dangerous experiment as support for other potential treatments that may similarly 
cause cancer. Of course, there is the possibility that the authors of the letter to the editor 
of Nature Methods are incorrect and had practiced flawed procedure, in which case 
CRISPR-Cas9 as a genetic technique is still considered relatively safe, but even this 
scenario highlights the importance of exercising the utmost caution in utilizing the 
technology and paying it the respect it demands. 
Treating a non-lethal vision impairment should not lead to the acquisition of a 
cancer diagnosis, and pretending the findings may not be muddy is a sure way to inhibit 
or prevent its implementation in the healthcare setting. Additionally, the opinion and 
perception of the public is a powerful force that can easily result in the rejection of such a 
technology if ignorance regarding its safety and efficacy spreads quicker than intended. 
Hence the need to focus on an ex vivo application of CRISPR-Cas13a instead of hurriedly 
rushing into an exciting frontier with CRISPR-Cas9 at the needless cost of even one 
human life. This preserves the possibility that CRISPR may one day produce Ehrlich’s 
much sought-after magic bullet that in the years and decades to come.  
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4. How the global community ought to proceed in using CRISPR to combat 
antibiotic resistance. 
 Having examined several of the possible uses of CRISPR and briefly touched on 
challenges to its implementation, it is important to establish how we ought to approach 
the problem of antibiotic resistance in the genetic era. Although CRISPR can be used by 
private individuals, it is not recommended, and will likely not place much of a dent in the 
issue of antibiotic resistance. Remember, it is easier to promote antibiotic resistance than 
to reverse it, so while an individual can contribute significantly to its spread, an 
individual will likely not resolve the issue very quickly. As such, this section will focus 
on larger-scale application of the technology and preach caution, both in healthcare 
settings and in global field settings. 
Recall that diagnostic testing is a key factor in limiting the accuracy and 
pointedness needed in treating bacterial infections and reducing antibiotic resistance. 
Most individuals who become sick do not have time to wait for lab results from the 
doctor’s office and as such doctors will prescribe antibiotic drug cocktails which are a 
mix of various broad-spectrum and narrow-spectrum antibiotics that can tackle a variety 
of the most common infections. However, in cases of antibiotic resistance this may not 
always work and may weaken the individual immune system by reducing bacterial 
competition from beneficial or harmless bacteria, placing the individual at greater risk. 
The CRISPR-Cas13a/C2c2 (SHERLOCK) mechanism previously described may be the 
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answer to this issue. Optimistically, this is the early integration of CRISPR in the 
healthcare setting as a diagnostic technique. This application is considered relatively safe, 
as it is an ex vivo RNA identification technique, requires only a small sample of blood 
from the infected individual, and significantly reduces both the time and cost of 
diagnostic testing such that it promotes more individualized prescription and treatment in 
the same medical appointment. The cost savings largely come from its ability to be mass 
produced rather quickly and in large quantities, as well as the benefit of isothermal 
amplification. Part of its appeal lies in the fact that it can be easily customized for use in 
various geographical regions or pandemic diseases, can be lyophilized, and can easily be 
stored for an extended amount of time which demonstrates improved shelf life; all of 
these factors of a CRISPR-based diagnostic test provide it clear advantages over current 
diagnostic methods used both in the field and in modern healthcare settings. There is little 
opposition or discussion surrounding this particular application, but that is in part because 
it is still being studied. However, I still contend that it is not yet ready for global 
application as it still suffers from issues that plague existing genotypic ASTs, and as such 
further development is needed. Despite this, its application, distribution, and remarkable 
specificity paint a promising future for a new class of genotypic ASTs and for combating 
antibiotic resistance worldwide. 
Though there is a temptation to view the CRISPR Pill as another magic bullet, it 
is a much riskier treatment, and is something that is not yet implementable. This can be 
discussed in two parts: 1) a pill that compliments or supplements existing antibiotics, or 
2) an ingestible or injectable CRISPR-based treatment that replaces an antibiotic 
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treatment. If the CRISPR pill shows real promise, the first step will likely be to use it in a 
fashion similar to that of combination drugs like Augmentin®. This may not be made 
available on the market very soon in part because it does carry the risk of mitochondrial 
dysfunction (toxicity). However, should future studies uncover clinically relevant doses 
administered with minimal negative effects in combination with existing antibiotics, this 
form of CRISPR pill will be the first commercially available option because this does not 
interfere with the human genome. The other option with an ingestible CRISPR-based 
treatment is to replace antibiotic treatment, but exactly what that might look like remains 
to be seen. Targets have yet to be identified, and the method of bacterial cell killing has 
not yet been detailed. Perhaps one option would be to incorporate synthetic genes into the 
human genome to combat certain bacterial infections, although the structure of such a 
gene is yet to be hypothesized and ethical discussions may prevent this from becoming an 
option. Additionally, phage therapy can be costly, although this may be relatively less so 
when compared to current phage therapies. Recall Fleming’s warnings surrounding the 
use of penicillin, and the discovery of anti-CRISPR genes, and suddenly it is obvious that 
resistance to a CRISPR-based treatment can be much deadlier and possibly be the end of 
our ability to address antibiotic resistance. The CRISPR pill, if not extensively researched 
for downstream effects, may end up hastening the pressing global issue at hand. For this 
reason, I suggest that the path forward avoids a CRISPR-based treatment until several 
years of research can be conducted surrounding its safety, disposal, and downstream 
effects. 
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As CRISPR-based technologies advance and phase into medical care, healthcare 
facilities must adapt their antimicrobial stewardship programs. Some may be resistant at 
first, instead opting not to use CRISPR-based treatment in favor of existing ones, but 
eventually the state of healthcare will have to evolve, because without large-scale effort 
to address the largest contributing source towards antibiotic resistance, bacteria will 
prevail. The state of research on the CRISPR-Cas system is not yet where it needs to be 
to create Paul Ehrlich’s ultimate magic bullet; however, with the rapid pace of 
development and the incredible efficiency of the CRISPR-Cas mechanism, a magic bullet 
may not be too far out of reach. Bacteria are not waiting, and neither should we, but we 
ought to exercise extreme prejudice and err on the side of caution to avoid a potentially 
more terrible fate than what we now face with antibiotic resistance. 
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